A5038832171- CAR-T cell therapy research
- Immune Cell Function and Interaction
- Thyroid Cancer Diagnosis and Treatment
- BRCA gene mutations in cancer
- Polyomavirus and related diseases
- Virus-based gene therapy research
- Immunotherapy and Immune Responses
- Biomarkers in Disease Mechanisms
- Advanced Breast Cancer Therapies
University of Padua
2023-2024
Vietnam National University Ho Chi Minh City
2021
Ho Chi Minh City University of Science
2021
Texas A&M University
2020
Background: The RET gene point mutation is the main molecular alteration involved in medullary thyroid carcinoma (MTC) tumorigenesis. Previous studies Vietnam mainly consisted of case reports, with limited data on larger sample sizes. In this study, we investigated mutations exons 10, 11, and 16 analyzed clinicopathological features a series Vietnamese MTC patients. Methods: We collected 33 tissue samples from patients using Sanger sequencing method. relationship between hotspot (exons 16)...
<h3>Background</h3> Patients affected by aggressive B-cell malignancies who are resistant to chemo-immunotherapy have an extremely poor prognosis and limited therapeutic options. Cytokine Induced Killer (CIK) cells gaining considerable clinical relevance, due the low risk of acute graft-versus-host disease (GvHD), their feasibility, production costs.<sup>1–3</sup> CIK a heterogeneous population CD3 CD56-expressing lymphocytes, expanded <i>ex vivo</i> peripheral blood mononuclear (PBMCs). In...
Breast cancer is the world's most common in women and leading cause of their cancer-related mortality. Its early diagnosis with conventional therapies such as surgery, chemotherapy, radiotherapy can give good results breast patients. However, these provide poor outcomes metastatic cancers or late-stage cancer. Therefore, another effort for treatment, immunotherapy now considered fourth-line treatment besides therapies. In this article, we focus on by transplantation cytokine-induced killer...
<h3>Background</h3> Cytokine-induced killer cells (CIKs) are a heterogeneous population of CD3 and CD56 expressing T lymphocytes, expanded activated <i>ex vivo</i> by peripheral blood mononuclear (PBMCs) or umbilical cord blood, with the addition interferon recombinant human-γ (rhIFN-γ), anti-CD3 monoclonal antibody (mAb), human interleukin-2 (rhIL-2). CIK gaining considerable clinical relevance, due to low risk acute graft-versus-host disease (GvHD) in both autologous allogeneic settings,...